Superseded public profile

Not FDA-approved↗Unapproved and safety records↗↗↗

Superseded · version 2: BPC-157↗

Related names recorded in this version: Body protection compound 157↗

A research peptide represented by FDA compounding-review material and one selected trial-registry record.↗↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 29, 2026

We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications. 14

What this version reported

FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • Hudson Biotech↗

Trial records: NCT07437547

Sources for this version

  1. 1
    FDA briefing document for BPC-157-related bulk drug substances ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  4. 4
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026